American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). Revised, 2010. [acesso em 24 Jul 2014]. Disponível em: http://www.auanet.org/common/pdf/education/clinical-guidance/Benign-Prostatic-Hyperplasia.pdf

Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Medicina Interna de Harrison. 18ª ed. Rio de Janeiro: McGraw-Hill, Artmed, 2013.

Rhoden EL, Riedner CE. Fármacos usados no tratamento da hiperplasia benigna de próstata. In: Fuchs FD, Wannmacher L (eds.). Farmacologia Clínica: Fundamentos da Terapêutica Racional. 4a. edição. Rio de Janeiro: Guanabara Koogan, 2010. P. 1120-29.

Sociedade Brasileira de Urologia. Sociedade Brasileira de Medicina de Família e Comunidade. Projeto Diretrizes: Hiperplasia Prostática Benigna. Associação Médica Brasileira e Conselho Federal de Medicina. Elaboração Final: 20 de junho de 2006. [acesso em: 25.07.2014]. Disponível em: http://www.projetodiretrizes.org.br

Barry MJ, Fowler FJ Jr, O’Leary MP,et. al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1549-57.

Webber R. Benign prostatic hyperplasia. In: BMJ Publishing Group. Clinical Evidence. London: BMJ Publishing Group Limited, 2006. Web publication date: 17 October 2006 [Acesso em 20 de novembro de 2006].

British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 65 ed. London: BMJ Publishing Group, APS Publishing, 2013.

Ding H, Du W, Hou ZZ, Wang HZ, Wang ZP. Silodosin is effective for treatment of LUTS in men with BPH: a systematic review. Asian J Andrology 2013; 15: 121-8;doi: 10.1038/aja.2012.102; published online 10 December 2012.

Canadian Agency for Drugs and Technologies in Health. Common Drug Review. CDEC Final Recommendation: Silodosin (Rapaflo - Watson Pharma Company). Indication: Prostatic Hyperplasia, Benign. CDEC Meeting - March 21, 2012, Notice of CDEC Final Recommendation - April 19, 2012. [acesso em 29. Jul 2014]. Disponível em: http://www.cadth.ca/media/cdr/complete/cdr_complete_Rapaflo_April-20-12.pdf

Cui Y, Zong H, Zhang Y. The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis. Int Urol Nephrol (2012) 44:1601–1609. DOI 10.1007/s11255-012-0261-6.

Novara G, Tubaro A, Sanseverino R, Spatafora S, Artibani W, Zattoni F, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol (2013) 31:997–1008. DOI 10.1007/s00345-012-0944-8